AnkeBio: Joint venture company Weisheng Pharmaceutical's long-acting growth hormone product Weizhengao has been approved for market in China.

According to Anke Biotechnology, on January 26th, its holding company, Weisheng Pharmaceutical, announced that its core product - the imported long-acting growth hormone Viscin has officially been approved for listing by the Chinese National Medical Products Administration for the treatment of pediatric growth hormone deficiency.